New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority For The Treatment Of Moderate To Severe Plaque Psoriasis

Podiatry Arena New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority For The Treatment Of Moderate To Severe Plaque Psoriasis

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority For The Treatment Of Moderate To Severe Plaque Psoriasis

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

28th November 2008, 06:20 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 3,061

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 5 Times in 5 Posts

New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority For The Treatment Of Moderate To Severe Plaque Psoriasis

Podiatry Arena members do not see these ads

Janssen-Cilag announced that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of adults with moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (CHMP). People living with psoriasis suffer not only from the symptoms of the disease itself, but also have to endure the burden and inconvenience of the treatments used to manage this chronic condition.

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is Off

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Non- Steroidal Combination Drug To Treat Psoriasis - Positive Phase 2b Results Showing Efficacy And Synergy DPS-101	RSSFeedBot	Latest Dermatology News	0	4th November 2008 01:21 PM
Synvista Therapeutics Receives Approval To Begin Phase 2 Trial Of Topical SYI-2074 In Psoriasis	RSSFeedBot	Latest Dermatology News	0	30th September 2008 02:40 AM
Risk attitudes to treatment among patients with severe intermittent claudication	NewsBot	Diabetic Foot & Wound Management	1	16th August 2008 07:18 AM
Possible New Treatment For Psoriasis	RSSFeedBot	Latest Dermatology News	0	8th August 2008 02:22 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 06:26 PM.

User Name		Remember Me?
Password